Synthekine: Funding, Investors & Team (Sep 2026)
A business called Synthekine is creating modified cytokine therapies for treating diseases. The business develops novel treatments for cancer and autoimmune diseases by using immunological insights to direct tailored protein engineering. Utilizing the ideas of immunological specificity and cytokine partial agonism, Synthekine creates differentiated therapies that are both effective and safe. In preclinical tests, its lead projects demonstrated encouraging efficacy and tolerability, and the company is currently working on the development of additional cytokine partial agonists that specifically alter important immune system pathways.
Synthekine has raised $290M across 3 funding rounds on record, the most recent a Series C of $100M announced in Jan 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Synthekine Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Synthekine Funding Rounds
Synthekine raised $82.0M in an undisclosed round announced in Sep 2020.
9 months later, an undisclosed round of $108M was announced in Jun 2021.
1.6 years later, a Series C of $100M was announced in Jan 2023.
Synthekine Founders and Leadership Team
Contact details for the Synthekine team: 1 of 2 have an email address on file.
Start 14-day free trial →Synthekine Funding Compared to Other Biotechnology Startups
Synthekine's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Synthekine in Biotechnology and Menlo Park
Companies Similar to Synthekine
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Synthekine Funding FAQs
What does Synthekine do?
A business called Synthekine is creating modified cytokine therapies for treating diseases. The business develops novel treatments for cancer and autoimmune diseases by using immunological insights to direct tailored protein engineering. Utilizing the ideas of immunological specificity and cytokine partial agonism, Synthekine creates differentiated therapies that are both effective and safe. In preclinical tests, its lead projects demonstrated encouraging efficacy and tolerability, and the company is currently working on the development of additional cytokine partial agonists that specifically alter important immune system pathways.
How much funding has Synthekine raised?
Synthekine has raised $290M across 3 rounds on record. The most recent is a Series C of $100M announced in Jan 2023.
When did Synthekine last raise funding?
Synthekine's most recent funding round on record is a Series C of $100M, announced in Jan 2023.
Who founded Synthekine?
FundedIQ lists K Christopher Garcia (Founder) at Synthekine.
Who is the CEO of Synthekine?
Debanjan Ray is listed as CEO at Synthekine.
Where is Synthekine headquartered?
Synthekine is based in Menlo Park, California, United States.
How many employees does Synthekine have?
Synthekine is in the 51-100 employee band.
How does Synthekine's funding compare to other Biotechnology startups?
Synthekine's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Synthekine Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Synthekine is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.